Annuncio pubblicitario
Italia markets closed
  • FTSE MIB

    33.629,21
    -107,19 (-0,32%)
     
  • Dow Jones

    38.675,68
    +450,02 (+1,18%)
     
  • Nasdaq

    16.156,33
    +315,37 (+1,99%)
     
  • Nikkei 225

    38.236,07
    -37,98 (-0,10%)
     
  • Petrolio

    77,99
    -0,96 (-1,22%)
     
  • Bitcoin EUR

    59.293,47
    +2.032,70 (+3,55%)
     
  • CMC Crypto 200

    1.359,39
    +82,41 (+6,45%)
     
  • Oro

    2.310,10
    +0,50 (+0,02%)
     
  • EUR/USD

    1,0765
    +0,0038 (+0,36%)
     
  • S&P 500

    5.127,79
    +63,59 (+1,26%)
     
  • HANG SENG

    18.475,92
    +268,79 (+1,48%)
     
  • Euro Stoxx 50

    4.921,48
    +30,87 (+0,63%)
     
  • EUR/GBP

    0,8577
    +0,0023 (+0,27%)
     
  • EUR/CHF

    0,9735
    -0,0024 (-0,25%)
     
  • EUR/CAD

    1,4726
    +0,0064 (+0,44%)
     

Altimmune to Participate at Two Upcoming Investor Conferences

Altimmune, Inc
Altimmune, Inc

GAITHERSBURG, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:

  • Wells Fargo 2023 Healthcare Conference in Everett, MA
    Wednesday, September 6, 2023
    Fireside chat at 3:45 pm Eastern Time

  • Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY
    Wednesday, September 13, 2023
    Fireside chat at 1:35 pm Eastern Time

The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.

ANNUNCIO PUBBLICITARIO

About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Altimmune Investor & Media Contact:

Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com